BloombergLean L·
Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO
Aspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 2% after raising about $140.6 million in a US initial public offering.
Read at Bloomberg →
Markets · 1 sources covering this
Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO
Aspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 2% after raising about $140.6 million in a US initial public offering.
Coverage spectrum
1 L · 0 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/0a368ce0f3ded1cc57a7fb6e355a2203bf76174b" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO"></iframe>
